Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces the completion of patient enrollment ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

Access to advanced cancer care is expanding in Norman and south-central Oklahoma with the grand opening of OU Health ...

A research project has reached an important milestone: the first treatment of an animal tumor with radioactive ion beams has ...